Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
α‐Synuclein is the major component of Lewy bodies and a candidate biomarker for neurodegenerative diseases in which Lewy bodies are common, including Parkinson's disease and dementia with Lewy bodies. A large body of literature suggests that these disorders are characterized by reduced concentrations of α‐synuclein in cerebrospinal fluid (CSF), with overlapping concentrations compared to healthy controls and variability across studies. Several reasons can account for this variability, including technical ones, such as inter‐assay and inter‐laboratory variation (reproducibility). We compared four immunochemical methods for the quantification of α‐synuclein concentration in 50 unique CSF samples. All methods were designed to capture most of the existing α‐synuclein forms in CSF (‘total’ α‐synuclein). Each of the four methods showed high analytical precision, excellent correlation between laboratories (R2 0.83–0.99), and good correlation with each other (R2 0.64–0.93), although the slopes of the regression lines were different between the four immunoassays. The use of common reference CSF samples decreased the differences in α‐synuclein concentration between detection methods and technologies. Pilot data on an immunoprecipitation mass spectrometry (IP‐MS) method is also presented. Our results suggest that the four immunochemical methods and the IP‐MS method measure similar forms of α‐synuclein and that a common reference material would allow harmonization of results between immunoassays. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · cited 2×
“…release could lead to lower a-synuclein in the CSF, whereas release from degenerating synapses/neurons could increase its CSF levels. a-Synuclein is also highly abundant in peripheral blood, making artificial blood contamination during the lumbar puncture a potential confounder (Hong et al. 2010).”
BackgroundSelf-citationAlpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608 · cited 1×
“Recently, sensitive assays that detect and amplify the biochemical signal of putative seeds of a-synuclein oligomers in CSF were published (Fairfoul et al. 2016; Shahnawaz et al. 2017; Groveman et al. 2018).”
BackgroundBittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374
Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141 · cited 2×
“…be a competition between aggregation of a-synuclein into Lewy bodies (LBs) and release of the protein from degenerating synapses (Ohrfelt et al. 2009; Mollenhauer et al. 2011; Tateno et al. 2012; Wennstrom et al. 2013; Slaets et al. 2014; Llorens et al. 2016), making the data complex to interpret.”
BackgroundImmunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132 · cited 2×
“In spite of the uncertainty regarding the diagnostic performance of CSF a-synuclein, because of an overlap in concentrations and discrepancies between study populations, there are several clinical trials in which a-synuclein expression, release, and/or aggregation are targeted (Valera and Masliah 2013).”
BackgroundTateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121
Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels
Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85
Cited by
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30024-9 · Cited by 673
Self-citationFluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
Self-citationBoiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C. (2020) · Cells · doi:10.3390/cells10010038 · Cited by 42
“For the determination of α -synuclein level, an ELISA from ADx neurosciences (Gent, Belgium), available through Euroimmun, was used [42].”
Self-citation
Metadata
- Authors
- Mollenhauer, B., Bowman, F. D., Drake, D., Duong, J., Blennow, K., El‐Agnaf, O., Shaw, L. M., Masucci, J., Taylor, P., Umek, R. M., Dunty, J. M., Smith, C. L., Stoops, E., Vanderstichele, H., Schmid, A. W., Moniatte, M., Zhang, J., Kruse, N., Lashuel, H. A., Teunissen, C., Schubert, T., Dave, K. D., Hutten, S. J., & Zetterberg, H.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2018-11-13
- Volume
- 149
- Issue
- 1
- Pages
- 126-138
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2888049920
- Cited by
- 55
- References
- 7
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.